Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-IP-10 Antibody · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Induction | EXPERIMENTAL | Placebo or Anti-IP-10 Antibody |
| Cohort 2: Induction | EXPERIMENTAL | Placebo or Anti-IP-10 Antibody |
| Cohort 3: Induction | EXPERIMENTAL | Placebo or Anti-IP-10 Antibody |
| Maintenance | EXPERIMENTAL | Placebo or Anti-IP-10 Antibody |
| Open Label | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks |
| Anti-IP-10 Antibody | DRUG | Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks |
Inclusion Criteria: * Clinical diagnosis of moderate to severe UC confirmed by endoscopic and histologic evidence * Mayo score ≥6 with an endoscopic subscore of ≥2 * Inadequate response and/or intolerance to one or more conventional therapy (i.e. oral aminosalicylates, immunosuppressants, corticost...
Anti-IP-10 Antibody is an investigational drug being studied for the treatment of moderate to severe ulcerative colitis, a form of inflammatory bowel disease. It is being developed by Bristol-Myers Squibb Company (BMY) and has completed a Phase 2 clinical trial.
Anti-IP-10 Antibody is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company conducted a Phase 2 clinical trial of the drug in patients with moderate to severe ulcerative colitis.
Anti-IP-10 Antibody is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial for ulcerative colitis has been completed.
Anti-IP-10 Antibody has one completed clinical trial, NCT01294410, titled 'Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis.' This Phase 2 trial enrolled 305 participants across multiple countries including the United States, Australia, and European nations.
Yes, Anti-IP-10 Antibody is also known as BMS-936557. The clinical trial NCT01294410, which studied the drug in ulcerative colitis, refers to it as BMS-936557 in its official title.